Kiadis continues collaboration of ATIR

Netherlands-based oncology focused biopharmaceutical firm Kiadis Pharma says that it is continuing its collaboration with Andrea Velardi, professor of clinical immunology at the University of Perugia, Italy on ATIR, a product in clinical development for enabling the use of a mismatched donor in a bone marrow transplantation by preventing acute graft versus host disease for end-stage leukemia patients. Under the agreement Prof Velardi will continue the development on the selective depletion of allo-reactive T cells from mismatched donors using Kiadis' ATIR. The company is preparing for a multi-center pivotal study on the product to start early 2009 and Prof Velardi will participate in this.